Teva downgraded to Hold from Buy at Maxim Maxim downgraded Teva to Hold after assuming coverage of the stock and lowered its price target for shares to $49 from $55. The firm expects a generic Copaxone approval and launch by June 2014.
Teva board authorizes increase in share repurchase program to $3B The Company announced today that, as authorized by the Board of Directors, it will increase its share repurchase program by $1.7 billion to $3 billion. The program has no time limitations. The Company intends to begin purchasing shares promptly.